Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2004-11-23
2008-07-22
Johannsen, Diana B (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C435S091200, C435S091500, C435S091510, C424S009200, C536S023500, C530S350000
Reexamination Certificate
active
07402388
ABSTRACT:
The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. FKBP markers are provided, wherein changes in the levels of expression of one or more of the FKBP markers is correlated with the presence of prostate cancer.
REFERENCES:
patent: 5030559 (1991-07-01), Nicolson et al.
patent: 5118611 (1992-06-01), Smith et al.
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5629007 (1997-05-01), Audia et al.
patent: 5635197 (1997-06-01), Audia et al.
patent: 5674682 (1997-10-01), Croce et al.
patent: 5688658 (1997-11-01), Diamandis
patent: 5723302 (1998-03-01), Diamandis
patent: 5763202 (1998-06-01), Horoszewicz
patent: 5801197 (1998-09-01), Steiner et al.
patent: 5843994 (1998-12-01), Samid
patent: 5854206 (1998-12-01), Twardzik et al.
patent: 5856112 (1999-01-01), Marley et al.
patent: 5859031 (1999-01-01), Hamilton et al.
patent: 5861248 (1999-01-01), Russell et al.
patent: 5882864 (1999-03-01), An et al.
patent: 5912253 (1999-06-01), Cottens et al.
patent: 5939258 (1999-08-01), Croce et al.
patent: 5945522 (1999-08-01), Cohen et al.
patent: 5968802 (1999-10-01), Wang et al.
patent: 5972615 (1999-10-01), An et al.
patent: 5976794 (1999-11-01), Katz et al.
patent: 5976838 (1999-11-01), Jacobs et al.
patent: 5985890 (1999-11-01), Cottens et al.
patent: 6011018 (2000-01-01), Crabtree et al.
patent: 6025137 (2000-02-01), Shyjan
patent: 6028174 (2000-02-01), Ullrich et al.
patent: 6034218 (2000-03-01), Reed et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6054265 (2000-04-01), Barney et al.
patent: 6166011 (2000-12-01), Wythes et al.
patent: 6200985 (2001-03-01), Cottens et al.
patent: 6251932 (2001-06-01), Reichelt et al.
patent: 6252058 (2001-06-01), Thompson
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6261766 (2001-07-01), Diamandis
patent: 6313264 (2001-11-01), Caggiano et al.
patent: 6319891 (2001-11-01), Sontheimer et al.
patent: 0 698 215 (1998-07-01), None
patent: 0 939 084 (1999-09-01), None
patent: 0 974 652 (2000-01-01), None
patent: 0 648 126 (2000-02-01), None
patent: WO 97/08318 (1997-03-01), None
patent: WO 97/33909 (1997-09-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 99/18210 (1999-04-01), None
patent: WO 99/37811 (1999-07-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 00/14234 (2000-03-01), None
patent: WO 00/18961 (2000-04-01), None
patent: WO 00/55174 (2000-09-01), None
patent: WO 00/55350 (2000-09-01), None
patent: WO 02/31209 (2002-04-01), None
Cleutijens, et al., “Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter,”The Journal of Biological Chemistry, vol. 271, No. 11, Mar. 15, 1996, pp. 6379-6388.
Henttu, et al., “Androgens Up-Regulate the Human Prostate-Specific Antigen Messenger Ribonucleic Acid (mRNA), but Down-Regulate the Prostatic Acid Phosphatase mRNA in the LNCaP Cell Line,”Endocrinology, vol. 130, No. 2, 1992, pp. 772.
Horoszewicz, et al., “LNCaP Model of Human Prostatic Carcinoma1,”Cancer Research, vol. 43, Apr. 1983, pp. 1809-1818.
Kokontis, et al., “Increased Androgen Receptor Activity and Altered c-mycExpression in Prostate Cancer Cells after Long-Term Androgen Deprivation1,”Cancer Research, vol. 54, Mar. 15, 1992, pp. 1566-1573.
Murtha, et al., “Androgen Induction of a Human Prostate-Specific Kallikrein,hKLK2: Characterization of an Androgen Response Element in the 5′ Promoter Region of the Gene554,”Biochemistry, vol. 32, 1993, pp. 6459-6464.
Schuurmans, et al., “Regulation Of Growth Of LNCaP Human Prostate Tumor Cells By Growth Factors And Steroid Hormones,”J. Steroid Biochem. Molec. Biol., vol. 40, No. 1-3, 1991, pp. 193-197.
Silverstein et al., “Different Regions of the Immunophilin FKBP52 Determine Its Association With the Glucocorticoid Receptor, hsp90, and Cytoplasmic Dynein,”Journal of Biological Chemistry, vol. 274, No. 52, Dec. 24, 1999, pp. 36980-36986.
Smith et al., “FKPB54, a Novel FK506-Binding Protein in Avian Progesterone Receptor Complexes and HeLa Extracts,”Journal of Biological Chemistry, vol. 268, No. 32, Nov. 15, 1993, pp. 24270-24273.
Swinnen, et al., “Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP,”Molecular and Cellular Endocrinology, vol. 104, 1994, pp. 153-162.
Swinnen, et al.,“Androgens Markedly Stimulate the Accumulation of Neutral Lipids in the Human Prostatic Adenocarcinoma Cell Line LNCaP,”Endocrinoloy, vol. 137, No. 10, 1996, pp. 4468-4474.
Tamayo, et al., “Interpreting patterns of gene expression with self-organizing maps: Methods and application to hematopoietic differentiation,”Proc. Natl. Acad. Sci. USA, vol. 96, Mar. 1999, pp. 2907-2912.
Ulrix et al., “Androgens Down-Regulate the Expression of the Human Homologue of Paternally Expressed Gene-3 in the Prostatic Adenocarcinoma Cell Line LNCaP,”Molecular and Cellular Endocrinology, vol. 155, 1999, pp. 69-76.
Ward et al., “Expression of the Estrogen Receptor-Associate Immunophilins, Cyclophilin 40 and FKPB52, in Breast Cancer,”Breast Cancer Research and Treatment, vol. 58, 1999, pp. 267-280.
Yang et al., “Differential Expression and Androgen Regulation of the Human Selenium-Binding Protein GenehSP56in Prostate Cancer Cells,”Cancer Research, vol. 58, Jul. 15, 1998, pp. 3150-3153.
Database GenBank Online, www.ncbi.nlm.nih.gov, Database Accession No. NM—004117, Apr, 5, 2003.
Zhu et al., “Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP,”Carcinogenesis, vol. 22, No. 9, Sep. 2001, pp. 1399-1402
Chung et al., “Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells,”Carcinogenesis, vol. 22, No. 8, Aug. 2001, pp. 1201.
Amler et al., “Dysregulated Expression of Androgen-responsive and Nonresponsive Genes in the Androgen-independent Prostate Cancer Xenograft Model CWR22-R,”Cancer Research, vol. 60, No. 21, Nov. 1, 2000, pp. 6134, 6139-6140.
Nair et al., “Molecular Cloning of Human FKBP51 and Comparisons of Immunophilin Interactions with Hsp90 and Progesterone Receptor,”Molecular and Cellular Biology, vol. 17, No. 2, Feb. 1997, pp. 594-595.
Bayoumi et al., “Cost-Effectiveness of Androgen Suppression Therapies in Advanced Prostate Cancer,” J. Natl. Cancer Inst., 92:1731-39 (2000).
GenBank Accession No. Q13451 (2007).
GenBank Accession No. Q13451 (2000).
Gillis Kimberly A.
Zhang Yixian
Fish & Richardson P.C.
Johannsen Diana B
LandOfFree
Expression analysis of FKBP54 in assessing prostate cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression analysis of FKBP54 in assessing prostate cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression analysis of FKBP54 in assessing prostate cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3963766